Prospective Validation of a Points Score System Predicting 30-day Survival
ConditionMetastatic Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorIndiana University
About this trial
This is a one-stage single-arm phase II clinical trial designed to prospectively test the survival prediction tool as developed by Lee et al on patients referred to radiation oncology for palliative treatments. Survival prediction score based on objective data including laboratory values, attendance to emergency room, and primary cancer origin will be assigned to each patient at time of enrollment.
Eligibility criteria
Qualifiers
Age ≥ 18 at time of consent
Ability to provide written informed consent
Cancer diagnosis referred to Radiation Oncology for palliative radiation therapy
Patients who either choose to not receive radiation therapy or not recommended to receive radiation therapy will remain eligible
Disqualifiers
Patients who are unable to participate in follow up visits per investigator discretion (virtual/phone follow up is permitted)
Patients who are receiving definitive/curative course of radiation therapy
Patients who self-report as pregnant or nursing
Trial design
Treatments tested in this trial
- Point score prediction tool for 30-day survival
Treatment groups
214 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov